This interaction simultaneously increased the survival of adriamycin-treated breast cancer cells, suggesting that inhibition of PD-1/PD-L1 may enhance the efficacy of chemotherapy in a non-immunological manner [6]. This evidence concerns the gene CD274 and breast carcinoma.